Ki16425
CAS No. 355025-24-0
Ki16425( Ki16425 | Ki-16425 | Ki 16425 )
Catalog No. M14214 CAS No. 355025-24-0
Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 51 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 49 | In Stock |
|
| 10MG | 86 | In Stock |
|
| 25MG | 188 | In Stock |
|
| 50MG | 360 | In Stock |
|
| 100MG | 503 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKi16425
-
NoteResearch use only, not for human use.
-
Brief DescriptionKi16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively.
-
DescriptionKi16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.
-
In VitroKi16425 (10 μM; 1.5 hours; HEK293A cells) treatment blocks LPA-induced dephosphorylation of YAP/TAZ in HEK293A cells. Ki16425 partially inhibits the ability of serum to repress YAP/TAZ phosphorylation, particularly at low serum concentrations (0.2%). Western Blot Analysis Cell Line:HEK293A cells Concentration:10 μM Incubation Time:1.5 hours Result:Blocked LPA-induced dephosphorylation of YAP/TAZ. Partially inhibited the ability of serum to repress YAP/TAZ phosphorylation.
-
In VivoKi16425 (Debio 0719) (1-30 mg/kg; i.p.; at 30 min prior to LPA injection) inhibits LPA-induced neuropathic pain-like behaviors. Animal Model:20-24 g male standard ddY-strain mice Dosage:1-30 mg/kg Administration:Intraperitoneal injection; at 30 minutes prior to LPA injection Result:LPA-induced neuropathic pain behaviors were attenuated in a dose-dependent manner.
-
SynonymsKi16425 | Ki-16425 | Ki 16425
-
PathwayGPCR/G Protein
-
TargetLPA Receptor
-
RecptorLPA1| LPA2| LPA3
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number355025-24-0
-
Formula Weight474.96
-
Molecular FormulaC23H23ClN2O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO:95 mg/mL (200.01 mM); Ethanol:95 mg/mL (200.01 mM); Water:<1 mg/mL (<1 mM)
-
SMILESO=C(O)CCSCC1=CC=C(C2=C(NC(OC(C3=CC=CC=C3Cl)C)=O)C(C)=NO2)C=C1
-
Chemical Name3-((4-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-3-methylisoxazol-5-yl)benzyl)thio)propanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Ki16198
Ki16198 is the methyl ester of Ki16425 which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM.
-
GRI977143
GRI977143 is a selective and non-lipid agonist of LPA2 (EC50 = 3.3 μM). GRI977143 inhibits the activation of caspases 3, 7, 8, and 9 and and reduces DNA fragmentation.
-
AM095 free acid
AM095 (free acid) is a potent LPA1 receptor antagonist (IC50s: 0.98 and 0.73 μM for recombinant human or mouse LPA1).In vitro, AM095 was a potent LPA receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA with IC values of 0.98 and 0.73 μM, respectively, and exhibited no LPA agonism.
Cart
sales@molnova.com